The Journal of Immunology, Vol 151, Issue 1 244-255, Copyright © 1993 by American Association of Immunologists

ARTICLES

Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2

PW Chen and HN Ananthaswamy
Department of Immunology, University of Texas M. D. Anderson Cancer Center, Houston 77030.

Tumor specific immunity is mediated by CTL that recognize peptide Ag in the context of MHC class I molecules and by Th cells that recognize peptide Ag in the context of MHC class II molecules. To clarify the relative importance of MHC class I and II Ag in tumor rejection, we transfected a K1735 melanoma that did not express constitutively either MHC class I or II Ag with H-2Kk and/or I-Ak genes and determined their tumorigenicity. K1735 transfectants expressing either Kk or Ak Ag alone produced tumors in normal C3H mice, whereas most transfectants that expressed both molecules were rejected in normal C3H mice but produced tumors in nude mice. However, the Ak Ag requirement can be substituted by IL-2 because transfection of Kk-positive/Ak-negative K1735 cells with the IL-2 gene also resulted in abrogation of tumorigenicity in normal C3H mice but not in nude mice. Similarly, transfection of Kk- negative/Ak-positive K1735 cells with IFN-gamma gene resulted in induction of MHC class I Ag as well as rejection of these tumors in normal C3H mice. The rejection of K1735 transfectants expressing Kk and Ak Ag in normal C3H mice required both CD4+ and CD8+ T cells. In addition, the transplantation immunity induced by K1735 transfectants expressing both Kk and Ak Ag completely cross-protected mice against challenge with Kk-positive transfectants but only weakly protected them against challenge with parental K1735 cells or Ak-positive transfectants. These results indicate that expression of either MHC class I or II Ag alone is insufficient to cause the rejection of K1735 melanoma in syngeneic hosts and that both Ag are necessary. In addition, our data suggest that the failure of Kk-positive K1735 cells to induce a primary tumor rejection response in normal C3H mice may result from their inability to induce the helper arm of the antitumor immune response.

This article has been cited by other articles:

				O. Christ, S. Matzku, C. Burger, and M. Zöller Interleukin 2-Antibody and Tumor Necrosis Factor-Antibody Fusion Proteins Induce Different Antitumor Immune Responses in Vivo Clin. Cancer Res., May 1, 2001; 7(5): 1385 - 1397. [Abstract] [Full Text]

				C. N. Baxevanis, I. F. Voutsas, O. E. Tsitsilonis, A. D. Gritzapis, R. Sotiriadou, and M. Papamichail Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor J. Immunol., April 1, 2000; 164(7): 3902 - 3912. [Abstract] [Full Text] [PDF]

				S. Manici, T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 J. Exp. Med., March 1, 1999; 189(5): 871 - 876. [Abstract] [Full Text] [PDF]

				F. Ossendorp, E. Mengede, M. Camps, R. Filius, and C. J.M. Melief Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors J. Exp. Med., March 2, 1998; 187(5): 693 - 702. [Abstract] [Full Text] [PDF]

				T. D. Armstrong, V. K. Clements, and S. Ostrand-Rosenberg MHC Class II-Transfected Tumor Cells Directly Present Antigen to Tumor-Specific CD4+ T Lymphocytes1 J. Immunol., January 15, 1998; 160(2): 661 - 666. [Abstract] [Full Text] [PDF]

				T. D. Armstrong, V. K. Clements, B. K. Martin, J. P.-Y. Ting, and S. Ostrand-Rosenberg Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity PNAS, June 24, 1997; 94(13): 6886 - 6891. [Abstract] [Full Text] [PDF]